Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Aug;39(8):1721–1725. doi: 10.1128/aac.39.8.1721

Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children.

J L Blumer 1, M D Reed 1, G L Kearns 1, R F Jacobs 1, W M Gooch 3rd 1, R Yogev 1, K Willims 1, B J Ewing 1
PMCID: PMC162815  PMID: 7486908

Abstract

Meropenem is a new carbapenem antibiotic which possesses a broad spectrum of antibacterial activity against many of the pathogens responsible for pediatric bacterial infections. In order to define meropenem dosing guidelines for children, an escalating, single-dose, pharmacokinetic study at 10, 20, and 40 mg/kg of body weight was performed. A total of 73 infants and children in four age groups were enrolled in the study: 2 to 5 months, 6 to 23 months, 2 to 5 years, and 6 to 12 years. The first patients enrolled were those in the oldest age group, who received the lowest dose. Subsequent enrollment was determined by decreasing age and increasing dose. Complete studies were performed on 63 patients. No age- or dose-dependent effects on pharmacokinetic parameter estimates were noted. Mean pharmacokinetic parameter estimates were as follows: half-life, 1.13 +/- 0.15 h; volume of distribution at steady state, 0.43 +/- 0.06 liters/kg; mean residence time, 1.57 +/- 0.11 h; clearance, 5.63 +/- 0.75 ml/min/kg; and renal clearance, 2.53 +/- 0.50 ml/min/liters kg. Approximately 55% of the administered dose was recovered as unchanged drug in the urine during the 12 h after dosing. No significant side effects were reported in any patients. By using the derived pharmacokinetic parameter estimates, a dose of 20 mg/kg given every 8 h will maintain plasma meropenem concentrations above the MIC that inhibits 90% of strains tested for virtually all potentially susceptible bacterial pathogens.

Full Text

The Full Text of this article is available as a PDF (270.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baquero F., Loza E. Antibiotic resistance of microorganisms involved in ear, nose and throat infections. Pediatr Infect Dis J. 1994 Jan;13(1 Suppl 1):S9–S22. doi: 10.1097/00006454-199401001-00003. [DOI] [PubMed] [Google Scholar]
  2. Bax R. P., Bastain W., Featherstone A., Wilkinson D. M., Hutchison M., Haworth S. J. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):311–320. doi: 10.1093/jac/24.suppl_a.311. [DOI] [PubMed] [Google Scholar]
  3. Besunder J. B., Reed M. D., Blumer J. L. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I). Clin Pharmacokinet. 1988 Apr;14(4):189–216. doi: 10.2165/00003088-198814040-00001. [DOI] [PubMed] [Google Scholar]
  4. Engelhard D., Shalit I., Stutman H. R., Greenwood R., Griffis J., Marks M. I. Single-dose pharmacokinetics of imipenem-cilastatin in pediatric patients. Pediatr Pharmacol (New York) 1986;5(4):273–279. [PubMed] [Google Scholar]
  5. Fujii R., Yoshioka H., Fujita K., Maruyama S., Sakata H., Inyaku F., Chiba S., Tsutsumi H., Wagatsuma Y., Fukushima N. [Pharmacokinetic and clinical studies with meropenem in the pediatric field. Pediatric Study Group of Meropenem]. Jpn J Antibiot. 1992 Jun;45(6):697–717. [PubMed] [Google Scholar]
  6. Fukasawa M., Sumita Y., Harabe E. T., Tanio T., Nouda H., Kohzuki T., Okuda T., Matsumura H., Sunagawa M. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother. 1992 Jul;36(7):1577–1579. doi: 10.1128/aac.36.7.1577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gavan T. L. In vitro antimicrobial susceptibility testing. Clinical implications and limitations. Med Clin North Am. 1974 May;58(3):493–503. doi: 10.1016/s0025-7125(16)32138-1. [DOI] [PubMed] [Google Scholar]
  8. Harrison M. P., Moss S. R., Featherstone A., Fowkes A. G., Sanders A. M., Case D. E. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):265–277. doi: 10.1093/jac/24.suppl_a.265. [DOI] [PubMed] [Google Scholar]
  9. Jacobs R. F., Kearns G. L., Trang J. M., Brown A. L., Marmer B., McIntosh J. C., Underwood F. L., Kluza R. B. Single-dose pharmacokinetics of imipenem in children. J Pediatr. 1984 Dec;105(6):996–1001. doi: 10.1016/s0022-3476(84)80098-0. [DOI] [PubMed] [Google Scholar]
  10. Jones R. N., Barry A. L., Thornsberry C. In-vitro studies of meropenem. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):9–29. doi: 10.1093/jac/24.suppl_a.9. [DOI] [PubMed] [Google Scholar]
  11. Klastersky J., Zinner S. H. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis. 1982 Mar-Apr;4(2):294–301. doi: 10.1093/clinids/4.2.294. [DOI] [PubMed] [Google Scholar]
  12. Ljungberg B., Nilsson-Ehle I. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob Agents Chemother. 1992 Jul;36(7):1437–1440. doi: 10.1128/aac.36.7.1437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Moellering R. C., Jr, Eliopoulos G. M., Sentochnik D. E. The carbapenems: new broad spectrum beta-lactam antibiotics. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):1–7. doi: 10.1093/jac/24.suppl_a.1. [DOI] [PubMed] [Google Scholar]
  14. Norrby S. R., Alestig K., Björnegård B., Burman L. A., Ferber F., Huber J. L., Jones K. H., Kahan F. M., Kahan J. S., Kropp H. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother. 1983 Feb;23(2):300–307. doi: 10.1128/aac.23.2.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Reed M. D., O'Brien C. A., Aronoff S. C., Klinger J. D., Blumer J. L. Ceftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients. Antimicrob Agents Chemother. 1984 Sep;26(3):318–321. doi: 10.1128/aac.26.3.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sarubbi F., Franzus B., Verghese A. Comparative activity of meropenem (SM-7338) against major respiratory pathogens and amikacin-resistant nosocomial isolates. Eur J Clin Microbiol Infect Dis. 1992 Jan;11(1):65–68. doi: 10.1007/BF01971276. [DOI] [PubMed] [Google Scholar]
  17. Schumacher G. E. Pharmacokinetic and microbiologic evaluation of dosage regimens for newer cephalosporins and penicillins. Clin Pharm. 1983 Sep-Oct;2(5):448–457. [PubMed] [Google Scholar]
  18. Sumita Y., Inoue M., Mitsuhashi S. In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338. Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):908–916. doi: 10.1007/BF01963782. [DOI] [PubMed] [Google Scholar]
  19. Wise R. In vitro and pharmacokinetic properties of the carbapenems. Antimicrob Agents Chemother. 1986 Sep;30(3):343–349. doi: 10.1128/aac.30.3.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wise R., Logan M., Cooper M., Ashby J. P., Andrews J. M. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob Agents Chemother. 1990 Aug;34(8):1515–1517. doi: 10.1128/aac.34.8.1515. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES